Kunos, G., Osei-Hyiaman, D., Btkai, S., Sharkey, K
Following administration in phase 1 and phase 2 clinical studies[16]: Time to maximum concentration (Tmax) occurs 12 to 72 hours after subcutaneous injection Dose-proportional pharmacokinetics observed across the therapeutic dose range (1 mg to 12 mg) Steady-state concentrations achieved after approximately 4 weeks of weekly dosing The fatty diacid conjugation enables albumin binding, extending circulation time Systemic exposure increases proportionally with dose escalation Distribution studies indicate widespread tissue distribution following absorption, with concentrations sufficient to engage receptor systems in metabolically relevant tissues including adipose tissue, liver, pancreas, and central nervous system regions involved in appetite regulation
Some individuals may experience mild nasal irritation or dryness
If you have a BMI of over 25, you may be an eligible candidate for treatment
A few get both at different points in the dose escalation
MQA Online Services, Licensure Verification
